How is functionning the Ethical Review Board « Comité d'Ethique Pour La Recherche En Obstétrique Et Gynécologie » (CEROG) ?


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 20 10 2021
revised: 15 02 2022
accepted: 01 03 2022
pubmed: 6 3 2022
medline: 6 4 2022
entrez: 5 3 2022
Statut: ppublish

Résumé

The French College of Gynecology and Obstetrics (CNGOF) has created an Ethical Review Board called the CEROG that aim to ensure the research projects are in conformity with the regulation and the laws, as well as to allow their publication in international scientific journals. The aim of this work was to analyze the work of this committee through the application received and to review the ethical procedures required by type of research project. We conducted a national retrospective study of all applications from 2018 to 2021 received by the CEROG Ethical Review Board. Each application must contain a verification of conformity with the MR004 regulation, a submission form and an information form to the patients involved. At reception, the documents are anonymized and then addressed to the members of one of the two independent sections (Obstetric and Prenatal diagnosis or Gynecology and Assisted Reproductive Therapy). Two hundred and sixty applications were received, including 52% in the Gynecology section and 48% in the Obstetrics' section. Only 10% (14/136) and 8% (10/124) were disapproved, respectively. In total, 35% of the applications to the Gynecology section leaded to publications in scientific journals but only 23% did so in the Obstetrics section. Most publications (60.8%) were in low impact factors journals (rank D and E). The Ethical Review Board CEROG is essential to ensure the conformity of the research projects with French regulations and allow fast publication in international journals.

Identifiants

pubmed: 35247608
pii: S2468-7847(22)00044-7
doi: 10.1016/j.jogoh.2022.102352
pii:
doi:

Substances chimiques

Cyclohexanes 0
Omite 2312-35-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102352

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Auteurs

Yohann Dabi (Y)

Service de Gynécologie Obstétrique et Biologie de la Reproduction, Sorbonne Université ; Hôpital Tenon, Assistance Publique des Hôpitaux de Paris (AP - HP), 4 rue de la Chine, Paris 75020, France. Electronic address: yohann.dabi@gmail.com.

Thibault Thubert (T)

Department of Obstetrics and Gynecology, University Hospital Center, 38 bvd Jean Monnet, Nantes, France; Centre D'investigation Clinique, Hopital Mere Enfant, CHU de Nantes, France.

Florent Fuchs (F)

Department of Obstetrics and Gynecology, University Hospital Center, 371 Avenue du Doyen Gaston Giraud, Montpellier, France; INSERM, CESP Center for Research in Epidemiology and Population Health, U1018, Reproduction and child development, Villejuif, France; INSERM, Institute Desbrest of Epidemiology and Public Health (IDESP), Université Montpellie, Montpellier, France.

Tiphaine Barjat (T)

Department of Gynecology and Obstetrics, Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France; INSERM U1059 SAINBIOSE, Université Jean Monnet, Saint-Étienne, France.

Joëlle Belaisch-Allart (J)

Service de Gynécologie Obstétrique et Médecine de la Reproduction, Centre Hospitalier des 4-Villes, Rue Lauer, 92210 Saint-Cloud, France.

Pierre Francois Ceccaldi (PF)

Service de Gynécologie-Obstétrique, Université de Paris ; Hôpital Beaujon, Service de Gynécologie-Obstétrique, Assistance Publique des Hôpitaux de Paris (AP - HP), Clichy la Garenne, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH